See more : Origin Materials, Inc. (ORGNW) Income Statement Analysis – Financial Results
Complete financial analysis of Qualigen Therapeutics, Inc. (QLGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Qualigen Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- ProPetro Holding Corp. (PUMP) Income Statement Analysis – Financial Results
- Quilter plc (QUILF) Income Statement Analysis – Financial Results
- Inpex Corporation (IPXHF) Income Statement Analysis – Financial Results
- MedinCell S.A. (MEDCL.PA) Income Statement Analysis – Financial Results
- YTL Corporation Berhad (4677.KL) Income Statement Analysis – Financial Results
Qualigen Therapeutics, Inc. (QLGN)
About Qualigen Therapeutics, Inc.
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.20M | 4.98M | 5.65M | 4.31M | 5.56M | 5.80M | 9.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 5.21M | 4.30M | 4.33M | 7.19M | 3.98M | 5.42M | 7.90M | 18.45M | 8.91M | 3.48K | 2.14K | 758.00 |
| Gross Profit | -4.50K | 680.80K | 1.32M | -2.88M | 1.58M | 378.39K | 1.87M | -18.45M | -8.91M | -3.48K | -2.14K | -758.00 |
| Gross Profit Ratio | -0.09% | 13.66% | 23.37% | -66.87% | 28.43% | 6.52% | 19.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.21M | 6.84M | 11.72M | 3.55M | 1.21M | 1.32M | 2.87M | 13.29M | 2.26M | 113.93K | 461.55K | 1.39M |
| General & Administrative | 6.10M | 10.84M | 11.72M | 8.02M | 1.51M | 1.05M | 4.78M | 4.88M | 6.40M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | -4.50K | 950.42K | 542.59K | 400.17K | 367.95K | 380.34K | 618.46K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.09M | 11.79M | 12.27M | 8.42M | 1.88M | 1.43M | 4.78M | 4.88M | 6.40M | 2.16M | 1.65M | 2.01M |
| Other Expenses | -5.21M | 1.13K | 5.45K | 0.00 | 2.79K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.10M | 18.62M | 23.98M | 17.40M | 3.08M | 1.42M | 7.65M | 18.17M | 8.66M | 2.28M | 2.11M | 3.40M |
| Cost & Expenses | 11.30M | 22.93M | 28.32M | 24.59M | 7.06M | 6.85M | 15.55M | 36.62M | 17.57M | 2.28M | 2.11M | 3.40M |
| Interest Income | 0.00 | 26.65K | 42.69K | 138.80K | 123.05B | 152.04K | 40.23K | 60.88K | 40.88K | 525.00 | 1.68K | 2.91K |
| Interest Expense | 1.52M | 26.65K | 0.00 | 0.00 | 283.10K | 0.00 | 0.00 | 0.00 | 0.00 | 213.52K | 6.08K | 54.64K |
| Depreciation & Amortization | 4.50K | 12.17K | 322.06K | 138.65K | 111.38K | 5.70K | 5.70K | 5.21K | 1.94K | 3.48K | 2.14K | 758.00 |
| EBITDA | -11.30M | -13.84M | -22.66M | -11.16M | -10.02M | -717.86K | -7.86M | -18.38M | -8.79M | -2.26M | -2.09M | -3.40M |
| EBITDA Ratio | -217.12% | -285.64% | -478.41% | -259.27% | -23.10% | -12.37% | -159.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -11.30M | -17.94M | -22.66M | -11.30M | -1.50M | -1.06M | -15.55M | -36.62M | -17.57M | -2.28M | -2.11M | -3.40M |
| Operating Income Ratio | -217.20% | -360.03% | -400.85% | -262.49% | -27.05% | -18.18% | -159.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.17M | 872.81K | 4.77M | -7.74M | 711.17K | -140.55K | 38.60K | 18.24M | 8.79M | -191.85K | 14.97K | -51.73K |
| Income Before Tax | -12.48M | -21.30M | -17.89M | -20.42M | -1.78M | -1.20M | -7.86M | -18.38M | -9.18M | -2.47M | -2.10M | -3.45M |
| Income Before Tax Ratio | -239.78% | -427.40% | -316.46% | -474.18% | -32.09% | -20.61% | -80.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -4.79K | -265.07K | 5.43K | 619.00 | 4.00K | 4.62K | 5.09K | -5.21K | -1.94K | 1.00 | 0.00 | 0.00 |
| Net Income | -13.42M | -21.03M | -17.90M | -20.42M | -1.79M | -1.20M | -7.86M | -18.38M | -9.18M | -2.47M | -2.10M | -3.45M |
| Net Income Ratio | -257.79% | -422.08% | -316.55% | -474.16% | -32.16% | -20.69% | -80.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.46 | -5.48 | -6.10 | -28.21 | -2.85 | -2.26 | -14.04 | -20.44 | -31.15 | -794.00 | -42.42K | -61.12K |
| EPS Diluted | -2.46 | -5.48 | -6.10 | -28.21 | -2.85 | -2.26 | -14.04 | -20.44 | -31.15 | -794.00 | -42.42K | -61.12K |
| Weighted Avg Shares Out | 5.07M | 3.84M | 2.93M | 723.72K | 627.00K | 530.47K | 560.22K | 899.33K | 294.68K | 3.12K | 62.30 | 62.30 |
| Weighted Avg Shares Out (Dil) | 5.07M | 3.84M | 2.93M | 723.72K | 627.00K | 530.47K | 560.22K | 899.33K | 294.68K | 3.12K | 62.30 | 62.30 |
Qualigen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
CARLSBAD, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today that CEO and Chairman Michael Poirier will...
Why Qualigen Therapeutics (QLGN) Stock Plunging After Q2 Update
Tucked in its Q2 earnings release, Qualigen Therapeutics Inc (NASDAQ: QLGN) announced deprioritizing the QN-165 COVID-19 program, sending shares to fall to a 52-week low. In July, the Company filed an FDA Investigational New Drug (IND) application to commence Phase 1b/2a clinical studies with QN-165...
Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19
CARLSBAD, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today the submission of an Investigational New Drug (IND) application...
Qualigen Therapeutics, Inc. to Present at the LD Micro Invitational XI Conference
CARLSBAD, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today that its CEO and Chairman Michael Poirier will present...
Qualigen Therapeutics, Inc. Appoints Tariq Arshad, MD, MBA as Chief Medical Officer
New Position Created to Deepen Clinical Expertise and Advance Pipeline Therapeutic Programs
Qualigen Therapeutics, Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update
Conference call scheduled for May 18, 2021 at 4:10 p.m. EDT.
Qualigen Therapeutics Plans to Combat COVID-19 Variants
Qualigen Therapeutics Inc (NASDAQ: QLGN) was one of the sponsors for the Benzinga Biotech Global Small Cap Conference that took place on March 24-25, 2021. The information contained in this article in no way represents investment advice or opinion on...
Why Is Qualigen Stock Trading Lower Today?
Qualigen Therapeutics Inc (NASDAQ: QLGN) shares are ticking lower as the company withdrew the FDA Emergency Use Authorization (EUA) application for its FastPack SARS-CoV-2 IgG diagnostic test for COVID-19 antibodies. According to the SEC filing, the EUA was submitted in June last...
Qualigen Therapeutics, Inc. Promotes Shishir Sinha to Chief Operating Officer Position
CARLSBAD, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, announced today that it has promoted long-time officer Shishir Sinha to...
Qualigen Therapeutics, Inc. to present at the Oppenheimer 31st Annual Healthcare Conference
CARLSBAD, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today that Michael Poirier, President, Chief Executive Officer and Chairman...
Source: https://incomestatements.info
Category: Stock Reports